Dr. Reddy's Laboratories Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.4%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
$0.51next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Revenues Quarterly335.9B
EBITDA Margin Quarterly2,280.0%Target: Above 25% over the medium term
Gross Margin Quarterly5,280.0%Target: Above 50% in FY27
Watch Items
- USFDA Regulatory InspectionsTrigger: Issuance of Warning Letters or Official Action Indicated (OAI) status at key manufacturing sitesAction: Conduct immediate remediation audits, engage external compliance consultants, and adjust product launch timelines.
- gRevlimid (Lenalidomide) Revenue CliffTrigger: Sharp decline in generic Revlimid sales in the US marketAction: Accelerate pipeline launches of complex generics, biosimilars, and expand ex-US branded generic markets.
Research as of 2 Sep 2026